Atlas Trials

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04280328 · COMPLETED

Trial details

NCT number
NCT04280328
Sponsor
Corvus Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2020-02-20
Primary completion
2021-09-21
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.